Axa S.A. Mersana Therapeutics, Inc. Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $727,155 - $1.01 Million	-128,700 Reduced 55.28%	104,100 $610,000
Q3 2022 Feb 14, 2023	BUY	$4.63 - $8.0 $1.03 Million - $1.78 Million	222,000 Added 2055.56%	232,800 $1.57 Million
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $1.03 Million - $1.78 Million	222,000 Added 2055.56%	232,800 $1.57 Million
Q1 2022 Feb 14, 2023	SELL	$3.74 - $6.63 $830,280 - $1.47 Million	-222,000 Reduced 95.36%	10,800 $43,000
Q1 2022 May 13, 2022	SELL	$3.74 - $6.63 $513,128 - $909,636	-137,200 Reduced 92.7%	10,800 $43,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $811,040 - $1.46 Million	148,000 New	148,000 $921,000
Q1 2021 May 14, 2021	SELL	$15.31 - $26.52 $3.14 Million - $5.44 Million	-205,042 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.84 - $27.59 $139,367 - $228,334	8,276 Added 4.21%	205,042 $5.46 Million
Q3 2020 Nov 13, 2020	SELL	$16.2 - $25.7 $1 Million - $1.59 Million	-61,931 Reduced 23.94%	196,766 $3.66 Million
Q2 2020 Aug 14, 2020	SELL	$5.24 - $23.4 $522,847 - $2.33 Million	-99,780 Reduced 27.83%	258,697 $6.05 Million
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $1.58 Million - $3.33 Million	358,477 New	358,477 $2.09 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.